An Open Label Dose Escalation Study Of E7080

Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor

NCT03009292 ·Status: COMPLETED ·Phase: PHASE1

An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors

NCT01773421 ·Status: COMPLETED ·Phase: PHASE1

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

NCT03477175 ·Status: COMPLETED ·Phase: PHASE2

A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

NCT01433991 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors

NCT00165802 ·Status: COMPLETED ·Phase: PHASE1

A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours

NCT00459823 ·Status: SUSPENDED ·Phase: PHASE1

Study of AS1411 in Advanced Solid Tumours

NCT00881244 ·Status: COMPLETED ·Phase: PHASE1

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

NCT00880308 ·Status: COMPLETED ·Phase: PHASE1

Phase 1 Study of E7090 in Subjects With Solid Tumor

NCT02275910 ·Status: COMPLETED ·Phase: PHASE1

A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors

NCT00869895 ·Status: COMPLETED ·Phase: PHASE1

A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors

NCT00921869 ·Status: COMPLETED ·Phase: PHASE1

A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies

NCT00130169 ·Status: COMPLETED ·Phase: PHASE1

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors

NCT00794781 ·Status: COMPLETED ·Phase: PHASE1

A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors

NCT06872580 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

Study of E7046 in Subjects With Selected Advanced Malignancies

NCT02540291 ·Status: TERMINATED ·Phase: PHASE1

Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer

NCT01449370 ·Status: COMPLETED ·Phase: PHASE1

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

NCT02501096 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

NCT05601219 ·Status: TERMINATED ·Phase: PHASE1

A Study of E7080 in Subjects With Solid Tumor

NCT01268293 ·Status: COMPLETED ·Phase: PHASE1

A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors

NCT00742131 ·Status: COMPLETED ·Phase: PHASE1

An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies

NCT00121732 ·Status: COMPLETED ·Phase: PHASE1

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

NCT02915172 ·Status: WITHDRAWN ·Phase: PHASE1

Study of E7389 Liposomal Formulation in Participants With Solid Tumor

NCT03207672 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement

NCT00882180 ·Status: COMPLETED ·Phase: PHASE1

A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors

NCT05829616 ·Status: UNKNOWN ·Phase: PHASE1